Introduction
For patients with reversible cardiac or respiratory injuries who would otherwise face grim outlooks and high mortality rate, extracorporeal membrane oxygenation (ECMO) continues to provide hope for successful recovery. The literature reports that hospital survival rates after being supported by ECMO range widely from 20% to 65%. 1, 2, 3, 4 Since the indications for ECMO used to support a patient with cardiac or respiratory failure can differ greatly, it is important to consider these two populations as different when doing specific analyses.
Patients on ECMO for cardiac failure are supported by veno-arterial (VA) ECMO.
ECMO provides reasonable recovery for patients suffering from cardiac failure as ECMO survival rates range from 50% to 69% 5, 6, 7, 8 and hospital discharge rates range from 25% to 45%. 7, 5, 9, 10 With the use of ECMO for patient salvage from refractory cardiogenic shock in adult populations increasing exponentially, a comprehensive analysis of risk factors associated with the treatment, with the aim of creating a simple risk model, has yet to be completed.
While the literature sets forth an impressive breadth of potential risk factors associated with cardiac ECMO mortality, there is no clear risk score that can predict the probability of survival for a patient requiring cardiac ECMO. 5-7, 11, 12 Even though several intensive care unit (ICU) risk models exist that predict mortality among all ICU patients, patients being supported on cardiac ECMO may have different risk and treatment profiles compared to other ICU populations.
These common risk scores such as Simplified Acute Physiology Score II (SAPS II), 13 Sequential
Organ Failure Assessment (SOFA), 14 and Acute Physiology And Chronic Health Evaluation II (APACHE II) 15 may not apply for cardiac ECMO patients.
The present study assesses the survival rate of cardiac ECMO patients at our institution and attempts to distil a concise and generalizable set of risk factors that apply to this sub-group of cardiogenic shock patients. Also, this study seeks to determine if the common ICU or disease specific risk models (SAPS II, SOFA, and APACHE II) apply to cardiac ECMO patients. While a number of these risk models have been tested in mixed ECMO patient populations previously, 16, 17, 18 many have yet to be assessed in a patient population specific to cardiac ECMO. Finally, using the risk factors generated, this study attempts to create and verify a new Simple Cardiac ECMO Score, which can be used preoperatively to predict ECMO mortality for cardiac ECMO patients.
Methods
Between August 2010, and June 2014, 107 adult ECMO procedures were performed at our institution. Among those, 73 ECMO procedures were primarily done for cardiac support. were considered to be significant.
Results
The 73 patients who received cardiac ECMO at our institution consisted of 47 males and 26 females with a mean age of 48 ± 14 years. The etiologies for ECMO in these patients were acute myocardial infraction (AMI) (n=19), acute on chronic heart failure (n=14), post-cardiotomy failure (n=13), malignant arrhythmia (n=11), myocarditis (n=5), Takotsubo cardiomyopathy (n=2), accidental hypothermia (n=2), acute rejection (n=2), pulmonary embolism (n=2), constrictive pericarditis (n=1), drug overdose cardiac arrest (n=1), and septic shock (n=1). The average duration of ECMO support in these patients was 9.2 ± 6.1 days. Among the 73 patients, 47 patients (64%) survived ECMO. Causes of death in patients who died on ECMO included anoxic brain injury (n=8), stroke (n=8), irreversible cardiac dysfunction (n=3), sepsis (n=3), irreversible lung disease (n=2), abdominal compartment syndrome with hepato-renal syndrome (n=1), and failure to control bleeding (n=1). There were no ECMO device related deaths.
Among the 47 ECMO survivors, 39 had improved or unchanged kidney function (83%), 44 had improved or unchanged liver function (94%), 46 had improved or unchanged lactate trend (98%), and 43 had improved or unchanged pulmonary edema represented by Murray score (91%) ( Table   1 ).
Among the ECMO survivors, 27/47 patients (57%) were discharged from the hospital.
Causes of death post-ECMO but prior to discharge included sepsis (n=5), neurologic injury (n=4), AMI due to stent thrombosis (n=2), family's withdrawal due to failure to thrive (n=2), and one case of each of the following: pulseless electric activity after internal defibrillator placement, persistent loss of cardiac activity despite biventricular assist device placement, acute failure of left ventricular assist device placement with persistent low flow and malperfusion, non-resectable cardiac metastasis (adenocarcinoma), and severe coagulopathy and multiple bleeding. Note that 3 patients required two separate cardiac ECMO runs within the same hospital stay. One of these patients died on the second ECMO run, while two died post ECMO removal.
After univariate analysis of potential pre-ECMO risk factors, high lactate levels (p=0.02), the presence of post-cardiotomy failure (p=0.03), and a RIFLE score injury or above (p=0.10)
were associated with ECMO mortality (Table 2 ). We performed separate analyses to attempt to identify the risk factors for hospital mortality. Only pre-ECMO bicarbonate levels correlated with hospital mortality (Survivors: 18.3 ± 5.2; Non-survivors: 22.2 ± 6.4; p=0.03).
A new Simplified Cardiac ECMO Score for ECMO mortality was built and applied to this sample. A potential pre-ECMO risk factor p-value less than or equal to 0.1 as determined by univariate analyses was considered to be a factor for inclusion into new ECMO score. It was found that the combination of elevated lactate (>2.0 mmol/dl), renal dysfunction (RIFLE score of 'injury' or above), and post-cardiotomy predicted death. According to multivariate logistic regression analysis, presence of high lactate and post-cardiotomy each had approximately a twofold greater contribution to the odds of dying on ECMO than the presence of renal dysfunction (Table 3) . When combining these parameters into a simply calculated score as shown in Table 3 , the Simplified Cardiac ECMO Scores (minimum = 0, maximum = 5) were significantly different between ECMO survivors and non-survivors (p<0.001), while no such differences were detected for among any of the other pre-ECMO ICU or disease-specific risk scores (Table 4 ). The mortality rates progressively increased with a higher Simplified Cardiac ECMO Score; mortality Table 5 ). Statistical significance was not reached relative to APACHE II and ECMOnet scores.
Discussion
The ECMO and hospital survival results from our institution are consistent with those from other previous studies of cardiac ECMO. 5, 6, 7, 9, 10 However, there remains limited data from previous studies to suggest which patients make good candidates for cardiac ECMO, and which patients are futile cases. While previous studies have determined various risk factors for cardiac ECMO patients, no studies to date have isolated a specific risk score for this patient population. By utilizing an easily calculated risk score for cardiac ECMO patients, physicians can evaluate in which patients the use of cardiac ECMO presents elevated risk of mortality.
While the majority of cardiac ECMO patients are supported in the ICU, traditional ICU risk scores do not apply because they utilize variables that do not apply to most ECMO patients.
For example, in the APACHE II, SOFA and SAPS II scores, PaO2 and FiO2 measures are irrelevant because most cardiac ECMO patients are intubated and in pulmonary edema. The inclusion of the Glasgow Coma Scale (GCS) is not warranted because most patients with cardiogenic shock are sedated. [13] [14] [15] In addition, the SAPS II score takes type of admission, and whether the patient has any chronic diseases into account, both of which are not pertinent data points for survival considerations of cardiac ECMO patients. 13 In a study that assessed patients started on ECMO for refractory post-cardiotomy shock, it was found that a EuroSCORE of greater than 20% was associated with mortality. 7 The EuroSCORE was designed to predict the mortality of patients who undergo cardiac surgery and it may co-relate to the outcomes of postcardiotomy failure patients; however, it has minimum value to patients without cardiac surgery.
ECMOnet and PRESERVE scores have both been shown to predict mortality in respiratory ECMO patients. 20, 21 While these patients are on ECMO support, the etiologies for ECMO in these patients differ greatly from those being supported on cardiac ECMO. As such, the predictors of death in these patients will vary from those of cardiac ECMO patients.
ECMOnet scores include measures on pre-ECMO length of stay and hypotension, neither of which are relevant for cardiac ECMO mortality assessments. 20 Cardiac ECMO patients are often given vasopressors, so their blood pressure readings can be artificially manipulated. Finally, the PRESERVE score uses many respiratory measures such as PEEP, plateau pressure, and status on mechanical ventilation-none of which are pertinent for cardiac ECMO patients. 21 Though respiratory function may be of utmost relevance to respiratory ECMO mortality, it bears little influence on cardiac ECMO mortality because of the differing etiologies for and courses of treatment. While a number of studies have assessed the ability of previously-verified risk scores to predict mortality in all ECMO patients (both cardiac and respiratory), because the etiologies for ECMO in these two patient groups differ so widely, it is our impression that these two populations must be considered separately. 1, 17, 18 An organ system-specific score, the MELD score, also showed a poor correlation with cardiac ECMO mortality. This is likely because the MELD score was designed specifically to predict mortality in patients with primary liver failure, but the liver dysfunction in cardiac ECMO patients are more likely secondary to cardiogenic shock. 22 The MELD score was primarily designed to evaluate patients for potential liver transplants, and a prerequisite for its usage is normal cardiac function. 22 Cardiac ECMO patients have severely compromised cardiac function, and the MELD score cannot be applied to this patient population.
One of the factors incorporated into the Simple Cardiac ECMO Score was a patient's RIFLE score, as RIFLE values greater than or equal to 'injury' were nearly significant (survivors: 10 while others have failed to find a connection. 6 Our patient sample demonstrated that elevated lactate levels independently predicted mortality in the population. This lactate level may reflect the degree of malperfusion prior to ECMO. We were unable to identify a series discrete lactate levels that progressively increased the utility of our model. Rather than investigating various cutoff points for lactate levels, we used a marker of 'normal' or 'abnormal' levels to keep our score easy and simple to calculate. Post-cardiotomy cardiogenic shock in our patient sample yielded significant mortality results, suggesting it greatly impacts cardiac ECMO survival as well. After performing multivariate analysis, both high lactate and post-cardiotomy had approximately double the predictive odds of renal dysfunction. Accordingly, we have given elevated lactate and the diagnosis of being post-cardiotomy double the weight of renal dysfunction in our scoring system.
The implementation of the Simplified Cardiac ECMO Score yielded an acceptable AUC value, suggesting beneficial clinical utility. In addition to the above listed shortcomings for the cardiac ECMO patient population, all the ICU, disease-specific, and other ECMO-specific scores are very difficult to calculate, and often require software to determine expected mortality. This can take valuable time when in an emergent situation, and can also potentially dissuade clinicians from using the scores at all. Importantly, the Simplified Cardiac ECMO is easy to calculate.
Unlike many other risk scores, physicians do not need an algorithm or calculator to calculate the Simple Cardiac ECMO Score. Clinicians who are treating the refractory cardiogenic patient can simply calculate this Simple Cardiac ECMO Score in their head to have a well-informed view of the patient's prognosis. The intention of this score is not to exclude patients from cardiac ECMO.
However, in a setting in which demand for ECMO exceeds the resources of a particular hospital, this score may help physicians allocate hospital resources appropriately. This scoring system may also help physicians determine the prognosis of patients on cardiac ECMO to assess potential recovery.
Because our sample size was limited, we were unable to show a statistically significant increase in AUC relative to two of the other risk scores analyzed. Moreover, we did not have a sufficient sample to rigorously validate the model. That said, the Simplified Cardiac ECMO Score did provide a significantly higher predictive capacity, as measured by AUC, relative to five other risk scores, and it provides an early guide to identify futile cases in this high-risk patient population. This study assesses risk factors for the cardiac ECMO procedure itself, rather than hospital discharge. This is because being successfully discharged from the hospital can be altered by many post-ECMO issues, and may not be directly related to the ECMO procedure. In fact, separate analyses showed that only pre-ECMO bicarbonate levels predicted hospital mortality and we failed to create risk model. This study was also limited by its retrospective nature from a single institution. Future research should use the Simplified Cardiac ECMO Score in larger samples of cardiac ECMO patients to determine its utility in accurately predicting ECMO mortality in the population when compared with other ICU risk scores.
Conclusion
Commonly used ICU and disease-specific risk scores do not accurately predict ECMO mortality for patients supported on ECMO for primary cardiac failure. The Simple Cardiac Lactate (mmol/L) 5.5 ± 4.5 1.6 ± 1.0
Murray score 2 ± 1.5 1 ± 0.9 
